SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Biocryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals is trending following strong quarterly financial results and encouraging clinical data for its long-acting HAE treatment, Navenibart, presented at the American Academy of Allergy, Asthma & Immunology meeting. This news is igniting renewed community debate about its undervalued status and the possibility of a short squeeze amidst significant short interest.

Codatta

XNY (Codatta) is trending as it showcases remarkable price strength and green candles, defying broader crypto market downturns. The community is buzzing about its technical breakouts and potential for explosive growth, fueled by its utility in powering AI's data future.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending following its approximately $7.8 billion acquisition of Arcellx, a strategic move to significantly expand its oncology portfolio with promising CAR-T cell therapy. This acquisition is generating considerable community discussion as a key step in diversifying beyond its strong HIV franchise and highlights ongoing M&A in the biotech space.

Monad is a high-performance Layer 1 blockchain that processes 10,000 transactions per second with near-zero fees. The platform delivers high performance without compromising on security or decentralization, creating the infrastructure needed for complex applications that require high-frequency activity.  One of Monad’s key innovations lies in how it handles transaction processing. Instead of processing transactions one at a time like traditional blockchains, Monad processes multiple transactions simultaneously through parallel execution.   The system separates the agreement process from the execution process, allowing validators to first agree on which transactions to include and in what order, then having more time to execute those transactions without slowing down consensus. This approach, combined with a custom-built database called MonadDB, dramatically increases throughput while maintaining accuracy.  Monad also offers complete EVM compatibility, where applications built for Ethereum work on Monad without any code modifications, and users can connect with familiar wallets like MetaMask just as they would on Ethereum. Developers can immediately tap into Ethereum's established ecosystem of tools, libraries, and applications while benefitting from Monad’s performance improvements. The platform also runs on consumer-grade hardware rather than expensive specialized equipment, making it accessible for more people to participate in securing the network.  Monad has raised approximately 244 million dollars in total funding across multiple rounds. The company secured 19 million dollars in a seed round in February 2023 led by Dragonfly Capital, followed by a 225 million dollar Series A round in April 2024 led by Paradigm at a 3 billion dollar valuation. Other notable investors include Electric Capital, Greenoaks, Coinbase Ventures, and prominent angel investors such as Naval Ravikant.

Monad

Monad is generating significant buzz due to its high-performance EVM-compatible layer-1 blockchain and attractive staking rewards, leading the community to confidently accumulate and discuss its impressive resilience and recent ecosystem integrations amidst general market downturns.

Occidental Petroleum Corp. engages in the exploration and production of oil and natural gas. It operates through the following segments: Oil and Gas, Chemical, and Midstream and Marketing. The Oil and Gas segment explores for, develops and produces oil and condensate, natural gas liquids, and natural gas. The Chemical segment manufactures and markets basic chemicals and vinyls. The Midstream and Marketing segment purchases, markets, gathers, processes, transports and stores oil, condensate, natural gas liquids, natural gas, carbon dioxide, and power. The company was founded in 1920 and is headquartered in Houston, TX.

Occidental Petroleum Corp.

Occidental Petroleum is a top discussion point with the community actively anticipating a significant price surge driven by escalating Middle East tensions and potential oil supply disruptions, while a strong earnings beat and dividend hike further bolster bullish sentiment.

ProShares Trust - ProShares Bitcoin ETF

ProShares Bitcoin Strategy ETF

ProShares Bitcoin Strategy ETF ($BITO) is trending as a significantly reduced dividend payout and Bitcoin's price correction trigger community discussions around potential share price erosion and a reverse stock split, while many investors actively accumulate, anticipating a rebound.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

USO is a major talking point as escalating Middle East tensions, ignited by confirmed US-Israeli strikes that killed Iran's Supreme Leader and subsequent Iranian retaliation, fuel intense speculation among the community about surging oil prices and significant disruptions to global shipping through the Strait of Hormuz.

ProShares Trust - ProShares UltraPro Short QQQ -3x Shares

ProShares UltraPro Short QQQ

SQQQ is trending as investors brace for potential market volatility, driven by escalating geopolitical tensions and widespread concerns over an overvalued tech sector, leading the community to actively discuss accumulating bearish positions and hedging against a Nasdaq downturn.

Make Iran Great Again

MIGA Crypto is trending as its community rallies around the newly launched "Make Iran Great Again" token, actively promoting its low market cap and locked liquidity. Discussions are centered on collective efforts to propel its value and potentially rival other politically themed meme coins.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending as discussions erupt over the reported death of Iran's Supreme Leader following U.S./Israel strikes; the community is sharply divided, with some celebrating a decisive move attributed to Trump's leadership, while others view it as a dangerous political distraction from the Epstein files with potential for wider global instability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Average Rating of "Moderate Buy" from Brokerages

Shares of Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) have been given an average recommendation of "Moderate Buy" by the six brokerages that are presently covering the firm, MarketBeat.com...

Editas Medicine (NASDAQ:EDIT) Share Price Crosses Below 50 Day Moving Average - Here's What Happened

Editas Medicine (NASDAQ:EDIT) Stock Crosses Below 50 Day Moving Average - What's Next...

Editas Medicine (NASDAQ:EDIT) Stock Crosses Below 50 Day Moving Average - What's Next?

Editas Medicine (NASDAQ:EDIT) Share Price Passes Below 50-Day Moving Average - What's Next...

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has received a consensus recommendation of "Moderate Buy" from the six brokerages that are currently covering the company, MarketBeat.com...

Cathie Wood shells out $1.3 million on biotech stock

On the final trading day of 2025, Cathie Wood put an eye-brow raising $1.33 million to work in Intellia Therapeutics (NTLA), scooping up 145,153 shares in the gene-editing play. For the most part, it...

Editas Medicine (NASDAQ:EDIT) Stock Price Down 2.9% - Should You Sell?

Editas Medicine (NASDAQ:EDIT) Shares Down 2.9% - Should You Sell...

Editas (EDIT) Down 8.3% Since Last Earnings Report: Can It Rebound?

Editas (EDIT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Editas Medicine, Inc. (NASDAQ:EDIT) Receives Consensus Recommendation of "Hold" from Analysts

Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) has been given an average rating of "Hold" by the twelve ratings firms that are currently covering the company, Marketbeat reports. Two equities...

Editas Medicine (NASDAQ:EDIT) CEO Sells $12,046.45 in Stock

Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 5,603 shares of the business's stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold...

Insider Selling: Editas Medicine (NASDAQ:EDIT) CEO Sells 5,603 Shares of Stock

Editas Medicine, Inc. (NASDAQ:EDIT - Get Free Report) CEO Gilmore Neil O'neill sold 5,603 shares of the stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of...

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA.

Editas Medicine Inc

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

EDIT
Editas Medicine Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest EDIT News

EDITEditas Medicine Inc